Description

BSE revokes the trading suspension on equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing trading to resume.

Summary

BSE has revoked the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075, ISIN: INE092O01028). The company operates in the pharmaceutical industry, providing quality medication at affordable prices. The company is actively operational with its plant located at GIDC Estate, Waghodia, Vadodara.

Key Points

  • Trading suspension has been revoked for Rekvina Laboratories Limited
  • Scrip Code: 526075
  • ISIN: INE092O01028
  • Company is actively operational in pharmaceutical sector
  • Registered and Corporate Address: 36-Sampatrao Colony, Opp. Express Hotel, Alkapuri, Vadodara-390007
  • Plant Location: 242/4, GIDC Estate, At & post Waghodia, Vadodara-391760
  • Managing Director: Amit Mukesh Shah (DIN: 01993211)
  • Group Company: Radiant Parenterals Limited
  • Recent auditor change from M/s. Jigar Adhyaru & Co. to M/s. Y.M. Shah & Co. due to completion of statutory term

Regulatory Changes

The revocation of trading suspension restores normal trading operations for the scrip, removing previously imposed trading restrictions.

Compliance Requirements

  • Company has paid listing fees to BSE
  • Company maintains active operational status
  • Auditor appointment complies with regulatory requirements regarding statutory tenure limits
  • No adverse actions reported from other exchanges in the last five years

Important Dates

  • Circular Date: December 30, 2025
  • Previous Auditor Term: 2019-20 to 2023-24 (M/s. Jigar Adhyaru & Co.)
  • Current Auditor Term: 2024-25 to 2028-29 (M/s. Y.M. Shah & Co.)

Impact Assessment

Market Impact: The revocation enables investors and traders to buy and sell shares of Rekvina Laboratories Limited on BSE, restoring market liquidity for the scrip. Shareholders who were unable to exit or enter positions during the suspension period can now transact freely.

Operational Impact: The company’s operational status remains active with no changes to its core pharmaceutical business. The removal of trading suspension indicates resolution of compliance issues or concerns that led to the original suspension, potentially improving investor confidence in the company’s governance and regulatory standing.

Impact Justification

Revocation of trading suspension allows investors to resume trading in the scrip, directly impacting liquidity and shareholder ability to transact